James W F Catto1,2,3, Pramit Khetrapal3, Federico Ricciardi4, Gareth Ambler5, Norman R Williams6, Tarek Al-Hammouri3, Muhammad Shamim Khan7, Ramesh Thurairaja7, Rajesh Nair7, Andrew Feber3, Simon Dixon8, Senthil Nathan3, Tim Briggs3, Ashwin Sridhar3, Imran Ahmad9, Jaimin Bhatt9, Philip Charlesworth10, Christopher Blick10, Marcus G Cumberbatch1,2, Syed A Hussain1,11, Sanjeev Kotwal12, Anthony Koupparis13, John McGrath14, Aidan P Noon2, Edward Rowe13, Nikhil Vasdev15, Vishwanath Hanchanale16, Daryl Hagan5, Chris Brew-Graves5, John D Kelly3. 1. Department of Oncology and Metabolism, University of Sheffield, Sheffield, England. 2. Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England. 3. Division of Surgery and Interventional Science, University College London, London, England. 4. Owlstone Medical, Cambridge, England. 5. Department of Statistical Science, University College London, London, England. 6. Surgical and Interventional Trials Unit (SITU), Division of Surgery and Interventional Science, University College London, London, England. 7. Department of Urology, Guys and St Thomas' NHS Foundation Trust, London, England. 8. Health Economics and Decision Science, NIHR Research Design Service Yorkshire and the Humber, University of Sheffield, Sheffield, England. 9. Queen Elizabeth University Hospital, Glasgow, Scotland. 10. The Harold Hopkins Department of Urology, Royal Berkshire NHS Foundation Trust, Reading, England. 11. Department of Medical Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England. 12. Pyrah Department of Urology, St James University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, England. 13. Department of Urology, North Bristol NHS Trust, Bristol, England. 14. Department of Urology, Royal Devon University Hospitals Foundation Trust and University of Exeter, Exeter, England. 15. Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, University of Hertfordshire, Hatfield, England. 16. Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, England.
Abstract
Importance: Robot-assisted radical cystectomy is being performed with increasing frequency, but it is unclear whether total intracorporeal surgery improves recovery compared with open radical cystectomy for bladder cancer. Objectives: To compare recovery and morbidity after robot-assisted radical cystectomy with intracorporeal reconstruction vs open radical cystectomy. Design, Setting, and Participants: Randomized clinical trial of patients with nonmetastatic bladder cancer recruited at 9 sites in the UK, from March 2017-March 2020. Follow-up was conducted at 90 days, 6 months, and 12 months, with final follow-up on September 23, 2021. Interventions: Participants were randomized to receive robot-assisted radical cystectomy with intracorporeal reconstruction (n = 169) or open radical cystectomy (n = 169). Main Outcomes and Measures: The primary outcome was the number of days alive and out of the hospital within 90 days of surgery. There were 20 secondary outcomes, including complications, quality of life, disability, stamina, activity levels, and survival. Analyses were adjusted for the type of diversion and center. Results: Among 338 randomized participants, 317 underwent radical cystectomy (mean age, 69 years; 67 women [21%]; 107 [34%] received neoadjuvant chemotherapy; 282 [89%] underwent ileal conduit reconstruction); the primary outcome was analyzed in 305 (96%). The median number of days alive and out of the hospital within 90 days of surgery was 82 (IQR, 76-84) for patients undergoing robotic surgery vs 80 (IQR, 72-83) for open surgery (adjusted difference, 2.2 days [95% CI, 0.50-3.85]; P = .01). Thromboembolic complications (1.9% vs 8.3%; difference, -6.5% [95% CI, -11.4% to -1.4%]) and wound complications (5.6% vs 16.0%; difference, -11.7% [95% CI, -18.6% to -4.6%]) were less common with robotic surgery than open surgery. Participants undergoing open surgery reported worse quality of life vs robotic surgery at 5 weeks (difference in mean European Quality of Life 5-Dimension, 5-Level instrument scores, -0.07 [95% CI, -0.11 to -0.03]; P = .003) and greater disability at 5 weeks (difference in World Health Organization Disability Assessment Schedule 2.0 scores, 0.48 [95% CI, 0.15-0.73]; P = .003) and at 12 weeks (difference in WHODAS 2.0 scores, 0.38 [95% CI, 0.09-0.68]; P = .01); the differences were not significant after 12 weeks. There were no statistically significant differences in cancer recurrence (29/161 [18%] vs 25/156 [16%] after robotic and open surgery, respectively) and overall mortality (23/161 [14.3%] vs 23/156 [14.7%]), respectively) at median follow-up of 18.4 months (IQR, 12.8-21.1). Conclusions and Relevance: Among patients with nonmetastatic bladder cancer undergoing radical cystectomy, treatment with robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy resulted in a statistically significant increase in days alive and out of the hospital over 90 days. However, the clinical importance of these findings remains uncertain. Trial Registration: ISRCTN Identifier: ISRCTN13680280; ClinicalTrials.gov Identifier: NCT03049410.
Importance: Robot-assisted radical cystectomy is being performed with increasing frequency, but it is unclear whether total intracorporeal surgery improves recovery compared with open radical cystectomy for bladder cancer. Objectives: To compare recovery and morbidity after robot-assisted radical cystectomy with intracorporeal reconstruction vs open radical cystectomy. Design, Setting, and Participants: Randomized clinical trial of patients with nonmetastatic bladder cancer recruited at 9 sites in the UK, from March 2017-March 2020. Follow-up was conducted at 90 days, 6 months, and 12 months, with final follow-up on September 23, 2021. Interventions: Participants were randomized to receive robot-assisted radical cystectomy with intracorporeal reconstruction (n = 169) or open radical cystectomy (n = 169). Main Outcomes and Measures: The primary outcome was the number of days alive and out of the hospital within 90 days of surgery. There were 20 secondary outcomes, including complications, quality of life, disability, stamina, activity levels, and survival. Analyses were adjusted for the type of diversion and center. Results: Among 338 randomized participants, 317 underwent radical cystectomy (mean age, 69 years; 67 women [21%]; 107 [34%] received neoadjuvant chemotherapy; 282 [89%] underwent ileal conduit reconstruction); the primary outcome was analyzed in 305 (96%). The median number of days alive and out of the hospital within 90 days of surgery was 82 (IQR, 76-84) for patients undergoing robotic surgery vs 80 (IQR, 72-83) for open surgery (adjusted difference, 2.2 days [95% CI, 0.50-3.85]; P = .01). Thromboembolic complications (1.9% vs 8.3%; difference, -6.5% [95% CI, -11.4% to -1.4%]) and wound complications (5.6% vs 16.0%; difference, -11.7% [95% CI, -18.6% to -4.6%]) were less common with robotic surgery than open surgery. Participants undergoing open surgery reported worse quality of life vs robotic surgery at 5 weeks (difference in mean European Quality of Life 5-Dimension, 5-Level instrument scores, -0.07 [95% CI, -0.11 to -0.03]; P = .003) and greater disability at 5 weeks (difference in World Health Organization Disability Assessment Schedule 2.0 scores, 0.48 [95% CI, 0.15-0.73]; P = .003) and at 12 weeks (difference in WHODAS 2.0 scores, 0.38 [95% CI, 0.09-0.68]; P = .01); the differences were not significant after 12 weeks. There were no statistically significant differences in cancer recurrence (29/161 [18%] vs 25/156 [16%] after robotic and open surgery, respectively) and overall mortality (23/161 [14.3%] vs 23/156 [14.7%]), respectively) at median follow-up of 18.4 months (IQR, 12.8-21.1). Conclusions and Relevance: Among patients with nonmetastatic bladder cancer undergoing radical cystectomy, treatment with robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy resulted in a statistically significant increase in days alive and out of the hospital over 90 days. However, the clinical importance of these findings remains uncertain. Trial Registration: ISRCTN Identifier: ISRCTN13680280; ClinicalTrials.gov Identifier: NCT03049410.
Authors: Stephen B Williams; Yong Shan; Usama Jazzar; Hemalkumar B Mehta; Jacques G Baillargeon; Jinhai Huo; Anthony J Senagore; Eduardo Orihuela; Douglas S Tyler; Todd A Swanson; Ashish M Kamat Journal: JAMA Surg Date: 2018-10-01 Impact factor: 14.766
Authors: Fabrizio Dal Moro; Georges P Haber; Peter Wiklund; Abdullah E Canda; Mevlana D Balbay; Arnulf Stenzl; Filiberto Zattoni; Joan Palou; Inderbir Gill; James W Catto Journal: Minerva Urol Nefrol Date: 2016-08-31 Impact factor: 3.720
Authors: Malte W Vetterlein; Jakob Klemm; Philipp Gild; Marlon Bradtke; Armin Soave; Roland Dahlem; Margit Fisch; Michael Rink Journal: Eur Urol Date: 2019-08-29 Impact factor: 20.096
Authors: David Jayne; Alessio Pigazzi; Helen Marshall; Julie Croft; Neil Corrigan; Joanne Copeland; Phil Quirke; Nick West; Tero Rautio; Niels Thomassen; Henry Tilney; Mark Gudgeon; Paolo Pietro Bianchi; Richard Edlin; Claire Hulme; Julia Brown Journal: JAMA Date: 2017-10-24 Impact factor: 56.272
Authors: Jeffrey J Leow; Alexander P Cole; Thomas Seisen; Joaquim Bellmunt; Matthew Mossanen; Mani Menon; Mark A Preston; Toni K Choueiri; Adam S Kibel; Benjamin I Chung; Maxine Sun; Steven L Chang; Quoc-Dien Trinh Journal: Eur Urol Date: 2017-08-10 Impact factor: 20.096
Authors: J Alfred Witjes; Harman Max Bruins; Richard Cathomas; Eva M Compérat; Nigel C Cowan; Georgios Gakis; Virginia Hernández; Estefania Linares Espinós; Anja Lorch; Yann Neuzillet; Mathieu Rouanne; George N Thalmann; Erik Veskimäe; Maria J Ribal; Antoine G van der Heijden Journal: Eur Urol Date: 2020-04-29 Impact factor: 20.096
Authors: Raed A Azhar; Danny Rabah; Abdullah M Alenizi; Adel Alammari; Ahmed Alasker; Ali A Alqahtani; Bader H Alsaikhan; Fahad A Alyami; Hassan M Alzahrani; Khalid I Alothman; Maher S Moazin; Mofarej Alhgbani; Mohammed Baghdadi; Mohammed F Alotaibi Journal: Urol Ann Date: 2022-07-18